Filed Pursuant to Rule 424(b)(3)
Registration No. 333-233429
PROSPECTUS
STWC
Holdings, Inc.
2,000,000 Shares of Common Stock
This prospectus relates to the 2,000,000 shares of Common Stock
(the “Shares”) of STWC Holdings, Inc. (“we,” “our,” “STWC,” or the “Company”),
$0.00001 par value per share, being registered for possible resale, from time to time, by the holder thereof. These Shares are
Shares that may be issued pursuant to an investment agreement which establishes a private equity line of credit (“Investment
Agreement”) with Tangiers Global, LLC (“Tangiers”), which is deemed to be a statutory underwriter. See the section
of this prospectus entitled “The Investment Agreement” for a description of the private equity line and the section
entitled “Selling Stockholders” for additional information about Tangiers.
The selling stockholder may sell its Shares at prevailing market
or privately negotiated prices, including (without limitation) in one or more transactions that may take place by ordinary broker’s
transactions, privately-negotiated transactions or through sales to one or more dealers for resale. The maximum number of Shares
that can be sold pursuant to the terms of this offering by the selling stockholder is (in the aggregate) 2,000,000 Shares. Funds
received by the selling stockholder will be immediately available to such selling stockholder for use by it. The Company will not
receive any proceeds from the sale of the selling stockholder’s Shares. However, we will receive the sale price of any Shares
that we sell to Tangiers pursuant to the private equity line. Any proceeds we receive from the sale of the Shares under the private
equity line will be used for general corporate purposes. All costs incurred in the registration of the Shares are being borne by
the Company.
The offering will terminate two years from the date that the
registration statement relating to the Shares is declared effective, unless earlier fully sold or terminated. The Company intends
to maintain the effectiveness of the registration statement of which this prospectus is a part and to allow selling stockholders
to offer and sell the Shares for a period of up to two years, unless earlier completely sold, pursuant to Rule 415 of the General
Rules and Regulations of the Securities and Exchange Commission (“SEC”).
Our common stock is quoted on the OTCQB, one of the OTC Markets
Group over-the-counter markets, under the trading symbol “STWC.” On August 7, 2019, the closing sale price for our
common stock was $0.70.
We are an “emerging
growth company” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”),
as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) and are subject to reduced public company
reporting requirements. This prospectus complies with the requirements that apply to an issuer that is an emerging growth company.
INVESTING IN OUR STOCK INVOLVES RISKS. YOU SHOULD
CAREFULLY CONSIDER THE RISK FACTORS BEGINNING ON PAGE 3 OF THIS PROSPECTUS.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus.
Any representation to the contrary is a criminal offense.
The date of this prospectus is September
10, 2019
TABLE OF CONTENTS
You should rely only on
the information contained in this prospectus, any prospectus supplement or in any free writing prospectus we may authorize to be
delivered or made available to you. We have not, and the selling stockholders have not, authorized anyone to provide you with different
information. We and the selling stockholders are not offering to sell, or seeking offers to buy, shares of our Common Stock in
jurisdictions where offers and sales are not permitted. The information contained in this prospectus is accurate only as of the
date of this prospectus, regardless of the time of delivery of this prospectus or any sale of shares of our Common Stock.
We incorporate by reference important information into this
prospectus. You may obtain the information incorporated by reference without charge by following the instructions under the section
of this prospectus entitled “Incorporation of Certain Information by Reference.” You should carefully read this prospectus
as well as additional information described under the section of this prospectus entitled “Incorporation of Certain Information
by Reference,” before deciding to invest in our common shares.
PROSPECTUS SUMMARY
The following summary highlights selected material information
contained in this prospectus. This summary does not contain all the information you should consider before investing in the securities.
Before making an investment decision, you should read the entire prospectus carefully, including the “Risk Factors”
section, the financial statements and the notes to the financial statements.
Our Company
Corporate History
The Company was originally incorporated on April 25, 2007, under
the laws of the State of Utah as 4th Grade Films, Inc. On August 19, 2014, pursuant to an Agreement to Exchange Securities
(the “Securities Exchange Agreement”), the Company acquired approximately 90% of the outstanding common stock of Strainwise,
Inc., a Colorado corporation (“Strainwise Colorado”), in exchange for 23,124,184 shares of our common stock. The Company
converted to a Colorado corporation on January 16, 2015.
Business Overview
The Company provides branding marketing, administrative, accounting,
financial and compliance services (“Fulfillment Services”) to entities in the cannabis retail, cultivation, and manufacturing
industry (the “Regulated Entities”).
The Company was established to provide the Fulfillment Services
to medical and retail stores, cultivation, and manufacturing facilities in the regulated cannabis industry throughout the United
States. The Fulfillment Services would only be provided to stores and facilities located in geographical areas where the governing
state and local ordinances allow for the unfettered provision of such services.
Additional Information
Our principal executive offices are
located at 1350 Independence Street, Suite 300, Lakewood, CO 80215, and our telephone number is (303) 736-2442. Our website is
www.strainwiseconsulting.com. Information on our website or any other website is not incorporated by reference into, and does not
constitute a part of, this prospectus.
Our Emerging Growth Company Status
As a company with less than $1.07 billion
in revenue during our last fiscal year, we qualify as an “emerging growth company” as defined in the JOBS Act. As an
emerging growth company, we may, for up to five years, take advantage of specified exemptions from reporting and other regulatory
requirements that are otherwise applicable generally to public companies. These exemptions include:
|
|
●
|
the presentation of only two years of audited financial statements and only two years of related Management’s Discussion and Analysis of Financial Condition and Results of Operations;
|
|
|
●
|
deferral of the auditor attestation requirement on the effectiveness of our system of internal control over financial reporting;
|
|
|
●
|
exemption from the adoption of new or revised financial accounting standards until they would apply to private companies;
|
|
|
●
|
exemption from compliance with any new requirements adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation or a supplement to the auditor’s report in which the auditor would be required to provide additional information about the audit and the financial statements of the Company; and
|
|
|
●
|
reduced disclosure about executive compensation arrangements.
|
We may take advantage of these provisions
until we are no longer an emerging growth company, which will occur on the earliest of (i) the last day of the fiscal year
following the fifth anniversary of our IPO, (ii) the last day of the fiscal year in which we have more than $1.07 billion
in annual revenue, (iii) the date on which we issue more than $1.0 billion of non-convertible debt over a three-year
period and (iv) the date on which we are deemed to be a “large accelerated filer,” as defined in Rule 12b-2
promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have elected to take advantage
of each of the exemptions for emerging growth companies.
Accordingly, the information that we
provide you may be different than what you may receive from other public companies in which you hold equity interests.
The Offering
We are registering the
resale of 2,000,000 shares of Common Stock by the selling stockholders named in this prospectus, or their permitted transferees.
|
Common Stock offered by selling stockholder
|
|
Up to 2,000,000 shares of our common stock, par value $0.00001 per share (the “Common Stock”) issuable upon exercise of an outstanding put option.
|
|
|
|
|
|
Common Stock outstanding before the offering
|
|
33,925,715 shares.
|
|
|
|
|
|
Common Stock to be outstanding after the offering
|
|
35,925,715 shares, assuming all of the Shares are put to the Investor.
|
|
|
|
|
|
Term of the offering
|
|
The selling stockholders will determine when and how they will dispose of the shares of Common Stock registered under this prospectus for resale.
|
|
|
|
|
|
Use of proceeds
|
|
We will not receive any proceeds from the sale of the Common Stock by the selling stockholders.
|
|
|
|
|
|
Risk factors
|
|
We have not generated significant revenues since our original inception in 2013 and do not have sufficient funds to meet our cash flow requirements for the next 12 months. We are also dependent upon the continued services of our CEO. There is also no public market for our Common Stock and we have no commitments to create any public trading market for our shares. See “Risk Factors” below.
|
RISK FACTORS
Purchase of our Common Stock has a high degree of risk. Before
you invest you should carefully consider the risks and uncertainties described below and the other information in this prospectus.
If any of the following risks occur, our business, operating results and financial condition could be harmed, and the value of
our stock could go down. This means you could lose all or a part of your investment.
Risks Related to Our Company and its Business:
We have a limited operating history, which may make it
difficult for investors to predict future performance based on current operations.
We have a limited operating history upon which investors may
base an evaluation of our potential future performance. In particular, we have not proven that we can profitably provide fulfillment
services to entities in the cannabis retail industry. As a result, there can be no assurance that we will be able to develop or
maintain consistent revenue sources, or that our operations will be profitable and/or generate positive cash flow.
Any forecasts we make about our operations may prove to be inaccurate.
We must, among other things, determine appropriate risks, rewards, and level of investment in our clients, respond to economic
and market variables outside of our control, respond to competitive developments and continue to attract, retain, and motivate
qualified employees. There can be no assurance that we will be successful in meeting these challenges and addressing such risks
and the failure to do so could have a materially adverse effect on our business, results of operations, and financial condition.
Our prospects must be considered in light of the risks, expenses, and difficulties frequently encountered by companies in the early
stage of development. As a result of these risks, challenges, and uncertainties, the value of your investment in the Shares could
be significantly reduced or completely lost.
We have incurred significant losses associated with our
current operations.
For the three months ended April 30, 2019, we had a net loss
of $431,484 and for year ended January 31, 2019, we incurred a net loss of $2,275,276. At April 30, 2019, we had an accumulated
deficit of $1,539,712. Any losses in the future could cause the quoted price of our Common Stock to decline or have a material
adverse effect on our financial condition, our ability to pay our debts as they become due, and on our cash flow.
Our future success depends on our key executive officers
and our ability to attract, retain, and motivate qualified personnel.
Our future success largely depends upon the continued services
of our executive officers and management team, in particular Erin Phillips, our CEO. If one or more of our executive officers is
unable or unwilling to continue in their present position, or if we lose our consultants, we may not be able to replace them readily,
if at all. Additionally, we may incur additional expenses to recruit and retain new executive officers or consultants. If any of
our executive officers or consultants joins a competitor or forms a competing company, we may lose some or all of our customers.
Finally, we do not maintain “key person” life insurance on any of our executive officers.
Because of these factors, the loss of the services of any of
these key persons could adversely affect our business, financial condition, and results of operations, and thereby an investment
in our Common Stock.
Our continuing ability to attract and retain highly qualified
personnel will also be critical to our success because we will need to hire and retain additional personnel as our business grows.
There can be no assurance that we will be able to attract or retain highly qualified personnel. We face significant competition
for skilled personnel in our industries. In particular, if the cannabis industry continues to grow, demand for personnel may become
more competitive. This competition may make it more difficult and expensive to attract, hire, and retain qualified managers and
employees. Because of these factors, we may not be able to effectively manage or grow our business, which could adversely affect
our financial condition or business. As a result, the value of your investment could be significantly reduced or completely lost.
We have entered into convertible loan transactions which
may have a material detrimental impact on our stock price and ownership structure.
We have agreed to repay an aggregate of $571,000 to four lenders
and in each instance the lender has the right to convert loans during periods in which we cannot repay them prior to maturity.
In the case of Power Up, we issued two one-year promissory notes in the aggregate principal amount of $156,000 in February and
March 2019 and can prepay each loan during the first six months of the term but cannot repay it thereafter until maturity one year
from the loan date. For Crown Bridge Partners, LLC, we issued a one-year promissory note in the principal amount of $100,000 in
April 2019 which likewise cannot be repaid after six months until maturity. We also issued a nine-month promissory note to FirstFire
Global Opportunities Fund LLC in the principal amount of $150,000 which also cannot be repaid after six months until maturity.
Further, we issued a six-month promissory note to Tangiers Global, LLC, the Selling Stockholder in this prospectus. After six months,
or in the case of the Tangiers’ note, after the maturity date, each lender has the option to convert some or all of the principal
and unpaid interest on the notes into shares of Common Stock at a discount of between 30% to 65% to the lowest trading price during
a specified period prior to the conversion date. Often such lenders convert a portion of the principal or interest and immediately
sell the shares into the open market, frequently resulting in a lower trading price. Subsequent conversions may occur based on
the lower trading price resulting in more shares being issued at ever lower prices in the ongoing conversion process. The lender
may again immediately sell the shares into the market resulting in an even lower trading price. This may continue until the maturity
date of the note or conversion of the principal, interest, penalties or other amounts due under the notes and generally results
in a significant number of shares being issued in the multiple stages of conversion. If our trading market is unable to absorb
the sale of shares by the lenders, the trading price of our shares may be drastically reduced, and the number of shares issued
may significantly dilute the ownership of existing shareholders. In addition, we are required to reserve for future issuance to
the lenders a number of shares equal to between six and eight times the number of shares into which the notes may be converted
at any time. These features of the loans may have a material adverse effect on our ability to secure future financing or may negatively
impact the equity purchase price of target companies. We may also be required to increase the number of shares authorized by our
Articles of Incorporation to reserve the number of shares required under the loan documents.
We face intense competition and many of our competitors
have greater resources that may enable them to compete more effectively.
The cannabis consulting industry in which we operate in general
is subject to intense and increasing competition. Some of our competitors may have greater capital resources, facilities, and diversity
of services, which may enable them to compete more effectively in this market. Our competitors may devote their resources to developing
and marketing services that will directly compete with our own fulfillment services. Due to this competition, there is no assurance
that we will not encounter difficulties in obtaining revenues and market share or in the industry. There are no assurances that
competition in our industry will not lead to reduced prices for our services. If we are unable to successfully compete with existing
companies and new entrants to the market, this will have a negative impact on our business and financial condition.
If we fail to protect our intellectual property, our business
could be adversely affected.
Our viability will depend, in part, on our ability to develop
and maintain the proprietary aspects of our intellectual property to distinguish our services from those of our competitors. We
rely on copyrights, trademarks, trade secrets, and confidentiality provisions to establish and protect our intellectual property.
We may not be able to enforce some of our intellectual property rights because cannabis is illegal under federal law.
Any infringement or misappropriation of our intellectual property
could damage its value and limit our ability to compete. We may have to engage in litigation to protect the rights to our intellectual
property, which could result in significant litigation costs and require a significant amount of our time. In addition, our ability
to enforce and protect our intellectual property rights may be limited in certain countries outside the United States, which could
make it easier for competitors to capture market position in such countries by utilizing technologies that are similar to those
developed or licensed by us.
Our business, financial condition, results of operations,
and cash flow may in the future be negatively impacted by challenging global economic conditions.
Future disruptions and volatility in global financial markets
and declining consumer and business confidence could lead to decreased levels of consumer spending. These macroeconomic developments
could negatively impact our business, which depends on the general economic environment and levels of consumer spending. As a result,
we may not be able to maintain our existing customers or attract new customers, or we may be forced to reduce the price of our
products. We are unable to predict the likelihood of the occurrence, duration, or severity of such disruptions in the credit and
financial markets and adverse global economic conditions. Any general or market-specific economic downturn could have a material
adverse effect on our business, financial condition, results of operations, and cash flow.
We may not be able to effectively manage our growth or
improve our operational, financial, and management information systems, which would impair our results of operations.
In the near term, we intend to expand the scope of our operational
activities significantly. If we are successful in executing our business plan, we will experience growth in our business that could
place a significant strain on our business operations, finances, management, and other resources. The factors that may place strain
on our resources include, but are not limited to, the following:
|
|
●
|
The need for continued development of our financial and information management systems;
|
|
|
●
|
The need to manage strategic relationships and agreements with manufacturers, customers, and partners;
and
|
|
|
●
|
Difficulties in hiring and retaining skilled management, technical, and other personnel necessary
to support and manage our business.
|
Additionally, our strategy envisions a period of rapid growth
that may impose a significant burden on our administrative and operational resources. Our ability to effectively manage growth
will require us to substantially expand the capabilities of our administrative and operational resources and to attract, train,
manage, and retain qualified management and other personnel. There can be no assurance that we will be successful in recruiting
and retaining new employees or retaining existing employees.
We cannot provide assurances that our management will be able
to manage this growth effectively. Our failure to successfully manage growth could result in our sales not increasing commensurately
with capital investments or otherwise materially adversely affecting our business, financial condition, or results of operations.
A drop in the retail price of cannabis products may negatively
impact our business.
The demand for cannabis products depends in part on the price
of commercially grown cannabis. Fluctuations in economic and market conditions that impact the prices of commercially grown cannabis,
such as increases in the supply of such cannabis and the decrease in the price of products using commercially grown cannabis, could
cause the demand for cannabis products to decline, which would have a negative impact on our business.
Federal regulation and enforcement may adversely affect
the implementation of cannabis laws and regulations may negatively impact our revenues and profits.
Currently, a majority of the states, plus the District of Columbia
and U.S. territories, have laws and/or regulations that recognize, in one form or another, legitimate medical and adult recreational
uses for cannabis. Many other states are considering similar legislation. Conversely, under the federal Controlled Substances Act,
the policies and regulations of the federal government and its agencies are that cannabis has no medical benefit and a range of
activities including cultivation and the personal use of cannabis is prohibited. Unless and until Congress amends the CSA with
respect to cannabis use, as to the timing or scope of any such potential amendments there can be no assurance, there is a risk
that federal authorities may enforce current federal law, and we may be deemed to be engaged in dispensing cannabis in violation
of federal law. Active enforcement of the current federal regulatory position on cannabis may thus indirectly and adversely affect
our revenues and profits. The risk of strict enforcement of the CSA in light of Congressional activity, judicial holdings, and
stated federal policy remains uncertain. In February 2017, the Trump administration announced that there may be “greater
enforcement” of federal laws regarding cannabis. Any such enforcement actions could have a negative effect on our business
and results of operations.
In an effort to provide guidance to federal law enforcement,
the DOJ has issued Guidance Regarding Marijuana Enforcement to all United States Attorneys in a memorandum from Deputy Attorney
General David Ogden on October 19, 2009, in a memorandum from Deputy Attorney General James Cole on June 29, 2011 and in a memorandum
from Deputy Attorney General James Cole on August 29, 2013. Each memorandum provides that the DOJ is committed to the enforcement
of the CSA, but, the DOJ is also committed to using its limited investigative and prosecutorial resources to address the most significant
threats in the most effective, consistent, and rational way. On January 4, 2018, Attorney General Jeff Sessions revoked the Ogden
Memo and the Cole Memos.
The DOJ has not historically devoted resources to prosecuting
individuals whose conduct is limited to possession of small amounts of marijuana for use on private property but has relied on
state and local law enforcement to address marijuana activity. In the event the DOJ reverses its stated policy and begins strict
enforcement of the CSA in states that have laws legalizing medical marijuana and recreational marijuana in small amounts, there
may be a direct and adverse impact to our business and our revenue and profits. Furthermore, H.R. 83, enacted by Congress on December
16, 2014, provides that none of the funds made available to the DOJ pursuant to the 2015 Consolidated and Further Continuing Appropriations
Act may be used to prevent certain states, including Nevada and California, from implementing their own laws that authorized the
use, distribution, possession, or cultivation of medical marijuana. This prohibition is currently in place until September 30,
2019.
Variations in state and local regulation, and enforcement
in states that have legalized cannabis, may restrict cannabis-related activities, which may negatively impact our revenues and
prospective profits.
Individual state laws do not always conform to the federal standard
or to other state laws. Several states have decriminalized cannabis to varying degrees, other states have created exemptions specifically
for medical cannabis, and several have both decriminalization and medical laws. As of the date of this prospectus, 10 states and
the District of Columbia, as well as two U.S. territories, have legalized the recreational use of cannabis. Variations exist among
states that have legalized, decriminalized, or created medical cannabis exemptions. For example, certain states have limits on
the number of cannabis plants that can be homegrown. In most states, the cultivation of cannabis for personal use continues to
be prohibited except for those states that allow small-scale cultivation by the individual in possession of medical cannabis needing
care or that person’s caregiver. Active enforcement of state laws that prohibit personal cultivation of cannabis may indirectly
and adversely affect our business and our revenue and profits.
If we are unable to obtain and maintain the permits and licenses
required to operate our business in compliance with state and local regulations in Oklahoma, Puerto Rico, or California, we may
experience negative effects on our business and results of operations.
California has only issued temporary cannabis licenses
and there is no guarantee we will receive permanent licenses.
Effective January 1, 2018, the State of California allowed for
adult-use cannabis sales. California’s cannabis licensing system is being implemented in two phases. First, beginning on
January 1, 2018, the State began issuing temporary licenses. Temporary licenses were initially issued for 90 days but have since
been extended twice by the State. Prior to the State completing its review of any annual licenses, the licensing authority determined
they would eliminate the need to have multiple licenses issued to each entity for both medical and adult use.
Prospective customers may be deterred from doing business
with a company with a significant nationwide online presence because of fears of federal or state enforcement of laws prohibiting
possession and sale of medical or recreational cannabis.
Our website is visible in jurisdictions where medicinal and/or
recreational use of cannabis is not permitted and, as a result, we may be found to be violating the laws of those jurisdictions.
Cannabis remains illegal under federal law.
Cannabis is a Schedule-I controlled substance and is illegal
under federal law. Even in those states in which the use of cannabis has been legalized, its use remains a violation of federal
law. Since federal law criminalizing the use of cannabis preempts state laws that legalize its use, strict enforcement of federal
law regarding cannabis would likely result in our inability to proceed with our business plan, especially in respect of our ownership
of dispensaries. In addition, our assets, including real property, cash, equipment and other goods, could be subject to asset forfeiture
because cannabis is still federally illegal.
In February 2017, the Trump administration announced that there
may be “greater enforcement” of federal laws regarding cannabis. In addition, on January 4, 2018, Attorney General
Jeff Sessions revoked the Ogden Memo and the Cole Memos. Any such enforcement actions could have a negative effect on our business
and results of operations.
We are not able to deduct some of our business expenses.
Section 280E of the Internal Revenue Code prohibits cannabis
businesses from deducting their ordinary and necessary business expenses, forcing us to pay higher effective federal tax rates
than similar companies in other industries. The effective tax rate on a cannabis business depends on how large its ratio of nondeductible
expenses is to its total revenues. Therefore, our cannabis business may be less profitable than it could otherwise be.
We may not obtain the necessary permits and authorizations
for our clients to operate their cannabis business.
We may not be able to obtain or maintain the necessary licenses,
permits, authorizations, or accreditations for our clients to operate their dispensary businesses, or may only be able to do so
at great cost. In addition, we may not be able to comply fully with the wide variety of laws and regulations applicable to the
cannabis industry. Failure to comply with or to obtain the necessary licenses, permits, authorizations, or accreditations could
result in restrictions on our ability to provide our fulfillment services, which could have a material adverse effect on our business.
If we incur substantial liability from litigation, complaints,
or enforcement actions, our financial condition could suffer.
Our participation in the cannabis industry may lead to litigation,
formal or informal complaints, enforcement actions, and inquiries by various federal, state, or local governmental authorities
against us. Litigation, complaints, and enforcement actions could consume considerable amounts of financial and other corporate
resources, which could have a negative impact on our sales, revenue, profitability, and growth prospects. Except for once case
which has been settled, we have not been, and are not currently, subject to any material litigation, complaint, or enforcement
action regarding cannabis brought by any federal, state, or local governmental authority.
We may have difficulty accessing the service of banks,
which may make it difficult for us to operate.
Since the use of cannabis is illegal under federal law, many
banks will not accept for deposit funds from businesses involved with the cannabis industry. Consequently, businesses involved
in the cannabis industry often have difficulty finding a bank willing to accept their business. The inability to open or maintain
bank accounts may make it difficult for us and our clients to operate our medical cannabis businesses. If any of our or our clients’
bank accounts are closed, we may have difficulty processing transactions in the ordinary course of business, including paying suppliers,
employees and landlords, which could have a significant negative effect on our operations.
We are dependent on the popularity of consumer acceptance
of produce and herbs.
Our ability to generate revenue and be successful in the continued
implementation of our business plan to provide fulfillment services and invest in clients’ dispensaries is dependent on consumer
acceptance and demand of cannabis products. Acceptance of our clients’ products will depend on several factors, including
availability, cost, and convenience. If these customers do not accept our clients’ products, or if our clients fail to meet
their customers’ needs and expectations adequately, our ability to continue generating revenues from these clients could
be reduced.
A drop in the retail price of commercially grown produce
may negatively impact the business of our clients and ultimately our business.
The demand for our clients’ products depends in part on
the price of commercially grown cannabis. Fluctuations in economic and market conditions that impact the prices of commercially
grown cannabis, such as increases in the supply of such cannabis and the decrease in the price of commercially grown cannabis,
could cause the demand for cannabis to decline, which would have a negative impact on the business of our clients and ultimately
our business.
Litigation may adversely affect our business, financial
condition, and results of operations.
From time to time in the normal course of our business operations,
we may become subject to litigation that may result in liability material to our financial statements as a whole or may negatively
affect our operating results if changes to our business operations are required. The cost to defend such litigation may be significant
and may require a diversion of our resources. There also may be adverse publicity associated with litigation that could negatively
affect customer perception of our business, regardless of whether the allegations are valid or whether we are ultimately found
liable. Insurance may not be available at all or in sufficient amounts to cover any liabilities with respect to these or other
matters. A judgment or other liability in excess of our insurance coverage for any claims could adversely affect our business and
the results of our operations.
Our management concluded that our internal control over
financial reporting was not effective as of April 30, 2019, which could result in material weaknesses in our financial reporting,
such as errors in our financial statements and in the accompanying footnote disclosures, that could require restatements.
As of April 30, 2019, management assessed the effectiveness
of our internal controls over financial reporting. Management concluded, as of the year then ended, that our internal controls
and procedures were not effective to detect the inappropriate application of U.S. GAAP rules. Management concluded that our internal
controls were adversely affected by deficiencies in the design or operation of our internal controls, which management considered
to be material weaknesses. These material weaknesses include the following:
|
|
●
|
lack of qualified and sufficient accounting personnel;
|
|
|
●
|
deficiencies in the period-end reporting process;
|
|
|
●
|
inadequate internal controls over the application of new accounting principles or the application
of existing accounting principles to new transactions;
|
|
|
●
|
inadequate internal controls relating to the authorization, recognition, capture, and review of
transactions, facts, circumstances, and events that could have a material impact on the company’s financial reporting process;
and
|
|
|
●
|
ineffective control environment due to lack of directors that are independent.
|
The failure to implement and maintain proper and effective internal
controls and disclosure controls could result in material weaknesses in our financial reporting, such as errors in our financial
statements and in the accompanying footnote disclosures that could require restatements. Investors may lose confidence in our reported
financial information and disclosure, which could negatively impact our stock price.
We do not expect that our internal controls over financial reporting
will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable,
not absolute, assurance that the control system’s objectives will be met. Further, the design of a control system must reflect
the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Controls
can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the
controls. Over time, controls may become inadequate because changes in conditions or deterioration in the degree of compliance
with policies or procedures may occur. Because of the inherent limitations in a cost-effective control system, misstatements due
to error or fraud may occur and not be detected.
Risks Related to Our Common Stock:
Disclosure requirements pertaining to penny stocks may
reduce the level of trading activity in the market for our Common Stock and investors may find it difficult to sell their shares.
Trading of our Common Stock will be subject to Rule 15g-9 of
the Securities and Exchange Commission, which rule imposes certain requirements on broker/dealers who sell securities subject to
the rule to persons other than established customers and “accredited investors.” For transactions covered by the rule,
brokers/dealers must make a special suitability determination for purchasers of the securities and receive the purchaser’s
written agreement to the transaction prior to sale. The Securities and Exchange Commission also has rules that regulate broker/dealer
practices in connection with transactions in “penny stocks”. Penny stocks generally are equity securities with a price
of less than $5.00 (other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided
that current price and volume information with respect to transactions in that security is provided by the exchange or system).
The penny stock rules require a broker/dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to
deliver a standardized risk disclosure document prepared by the Securities and Exchange Commission that provides information about
penny stocks and the nature and level of risks in the penny stock market. The broker/dealer also must provide the customer with
current bid and offer quotations for the penny stock, the compensation of the broker/dealer and its salesperson in the transaction
and monthly account statements showing the market value of each penny stock held in the customer’s account. The bid and offer
quotations, and the broker/dealer and salesperson compensation information, must be given to the customer orally or in writing
prior to effecting the transaction and must be given to the customer in writing before or with the customer’s confirmation.
The beneficial ownership of our Common Stock is concentrated
among existing executive officers and directors.
Our Chairman and CEO, Erin Phillips, and our President, Matthew
Willer, beneficially own, in the aggregate, approximately 76% of the issued and outstanding Common Stock, almost all of which is
owned by Ms. Phillips. As a result, Ms. Phillips will be able to exercise a significant level of control over all matters requiring
shareholder approval, including the election of directors, amendments to our Articles of Incorporation, and approval of significant
corporate transactions. This control could have the effect of delaying or preventing a change of control or changes in management
and will make the approval of certain transactions difficult or impossible without the support of these shareholders.
The public trading market for our Common Stock may be
volatile and will likely result in higher spreads in stock prices.
Our Common Stock trades in the over-the-counter market. The
over-the-counter market for securities has historically experienced extreme price and volume fluctuations during certain periods.
These broad market fluctuations and other factors, such as our ability to implement our business plan, as well as economic conditions
and quarterly variations in our results of operations, may adversely affect the market price of our Common Stock. In addition,
the spreads on stock traded through the over-the-counter market are generally unregulated and higher than on stock exchanges, which
means that the difference between the price at which shares could be purchased by investors on the over-the-counter market compared
to the price at which they could be subsequently sold would be greater than on these exchanges. Significant spreads between the
bid and asked prices of the stock could continue during any period in which a sufficient volume of trading is unavailable or if
the stock is quoted by an insignificant number of market makers. Our trading volume may not be sufficient to significantly reduce
this spread, or we may not have sufficient market makers to affect this spread. These higher spreads could adversely affect investors
who purchase the shares at the higher price at which the shares are sold, but subsequently sell the shares at the lower bid prices
quoted by the brokers. Unless the bid price for the stock increases and exceeds the price paid for the shares by the investor,
plus brokerage commissions or charges, shareholders could lose money on the sale. For higher spreads such as those on over-the-counter
stocks, this is likely a much greater percentage of the price of the stock than for exchange listed stocks. There is no assurance
that at the time the shareholder wishes to sell the shares, the bid price will have sufficiently increased to create a profit on
the sale.
We have not paid, and do not intend to pay in the near
future, dividends on our common shares and therefore, unless our Common Stock appreciates in value, our shareholders may not benefit
from holding our Common Stock.
We have not paid any cash dividends since inception. Although
we anticipate allocating funds for payment of dividends from future earnings, if any, we do not anticipate this occurring until
we establish our primary business operations, of which there is no assurance. Therefore, any return on the investment made in our
shares of Common Stock will likely be dependent initially upon the shareholder’s ability to sell our common shares in the
open market, if one should develop, at prices exceeding the amount paid for our common shares and broker commissions on the sales.
We are an “emerging growth company,” and will
be able take advantage of reduced disclosure requirements applicable to “emerging growth companies,” which could make
our Common Stock less attractive to investors.
We are an “emerging growth company,” as defined
in the Jumpstart Our Business Startups Act of 2012, or JOBS Act, and, for as long as we continue to be an “emerging growth
company,” we intend to take advantage of certain exemptions from various reporting requirements applicable to other public
companies but not to “emerging growth companies,” including, but not limited to, not being required to comply with
the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive
compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory
vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We could be an
“emerging growth company” for up to five years, or until the earliest of (i) the last day of the first fiscal year
in which our annual gross revenues exceed $1 billion, (ii) the date that we become a “large accelerated filer” as defined
in Rule 12b-2 under the Exchange Act, which would occur if the market value of our Common Stock that is held by non-affiliates
exceeds $700 million as of the last business day of our most recently completed second fiscal quarter, or (iii) the date on which
we have issued more than $1 billion in non-convertible debt during the preceding three year period. We cannot predict if investors
will find our Common Stock less attractive if we choose to rely on these exemptions. If some investors find our Common Stock less
attractive as a result of any choices to reduce future disclosure, there may be a less active trading market for our Common Stock
and our stock price may be more volatile.
Our board of directors can, without
stockholder approval, cause preferred stock to be issued on terms that adversely affect Common Stockholders.
Under our articles of incorporation, our board of directors
is authorized to issue up to 20,000,000 shares of preferred stock, none of which are issued and outstanding as of the date of this
prospectus, and to determine the price, rights, preferences, privileges and restrictions, including voting rights, of those shares
without any further vote or action by our stockholders. If the board causes any additional preferred stock to be issued, the rights
of the holders of our Common Stock could be adversely affected. The board’s ability to determine the terms of preferred stock
and to cause its issuance, while providing desirable flexibility in connection with possible acquisitions and other corporate purposes,
could have the effect of making it more difficult for a third party to acquire a majority of our outstanding voting stock. Preferred
shares issued by the board of directors could include voting rights, or even super voting rights, which could shift the ability
to control the company to the holders of the preferred stock. Preferred shares could also have conversion rights into shares of
Common Stock at a discount to the market price of the Common Stock which could negatively affect the market for our Common Stock.
In addition, preferred shares would have preference in the event of liquidation of the corporation, which means that the holders
of preferred shares would be entitled to receive the net assets of the corporation distributed in liquidation before the Common
Stock holders receive any distribution of the liquidated assets. We have no current plans to issue any additional shares of preferred
stock.
FORWARD-LOOKING STATEMENTS
The statements contained in this prospectus that are not historical
facts are forward-looking statements that represent management’s beliefs and assumptions based on currently available information.
Forward-looking statements include the information concerning our possible or assumed future results of operations, business strategies,
competitive position, potential growth opportunities, potential operating performance improvements, ability to retain and recruit
personnel, the effects of competition, and the effects of future legislation or regulations. Forward-looking statements include
all statements that are not historical facts and can be identified by the use of forward-looking terminology such as the words
“believes,” “intends,” “may,” “should,” “anticipates,” “expects,”
“could,” “plans,” or comparable terminology or by discussions of strategy or trends. Although we believe
that the expectations reflected in such forward-looking statements are reasonable, we cannot give any assurances that these expectations
will prove to be correct. Such statements by their nature involve risks and uncertainties that could significantly affect expected
results, and actual future results could differ materially from those described in such forward-looking statements.
Among the factors that could cause actual future results to
differ materially are the risks and uncertainties discussed in this prospectus. While it is not possible to identify all factors,
we continue to face many risks and uncertainties including, but not limited to, the following:
|
|
●
|
Our ability to achieve profitability;
|
|
|
●
|
our estimates of our expenses, ongoing losses, future revenues, capital requirements, and our need
for additional financing;
|
|
|
●
|
our ability to obtain additional financing;
|
|
|
●
|
our estimates of the costs, timing, progress, and results of operations with respect to our fulfillment
services for the cannabis industry;
|
|
|
●
|
the nature and effect of any future laws, regulations, rules, regulations, interpretations, policies,
or procedures, when and if promulgated, could have on our business;
|
|
|
●
|
our ability to comply with existing and new government regulations;
|
|
|
●
|
our dependence on state laws and regulations regarding the cannabis industry;
|
|
|
●
|
our ability to retain key personnel;
|
|
|
●
|
our ability to maintain our key relationships with partners and service providers;
|
|
|
●
|
our ability to manage our growth effectively;
|
|
|
●
|
our ability to compete with competitors that may have greater resources than us;
|
|
|
●
|
global economic and political conditions; and
|
|
|
●
|
our competitive technology positions and operating interruptions (including, but not limited to,
labor disputes, leaks, fires, flooding, landslides, power outages, explosions, unscheduled downtime, transportation interruptions,
war and terrorist activities).
|
Should one or more of these risks materialize (or the consequences
of such a development worsen), or should the underlying assumptions prove incorrect, actual results could differ materially from
those expected. We disclaim any intention or obligation to update publicly or revise such statements whether as a result of new
information, future events or otherwise. These risks could cause our results to differ materially from those expressed in forward-looking
statements.
USE OF PROCEEDS
We will not receive any proceeds from the sale of the Shares
by the Selling Stockholder. However, we will receive the sale price of any Shares that we sell to Tangiers pursuant to the private
equity line.
THE INVESTMENT AGREEMENT
On June 20, 2019, we entered into an Investment Agreement with
Tangiers for the potential future issuance and purchase of shares of our Common Stock. The Investment Agreement establishes what
is sometimes termed a private equity line of credit or an equity drawdown facility. In general, the private equity line provides
that Tangiers has committed to purchase, from time to time over a 36-month period, shares of our Common Stock for cash consideration
of up to an aggregate of $10,000,000, subject to certain conditions and restrictions.
The amount of proceeds that we choose to draw down and receive
from the sale of shares under the private equity line will depend on a number of factors. The number of shares that we may sell
at any time is limited by the trading volume of our stock and limits on the percentage of our stock that Tangiers may own at any
time. We may also choose to not sell the full amount under the equity line available to us if we are able to sell our shares at
more favorable prices in other transactions. The Company and Tangiers selected $10,000,000 as the aggregate amount issuable by
the Company under the private equity line based on Tangiers’ experience providing similar financing to other companies and
based on STWC’s projections of the amount of such financing that we might need over a period of three years.
Shares of Common Stock issued to Tangiers under the Investment
Agreement will be issued pursuant to an exemption from registration under the Securities Act of 1933, as amended. In connection
with the Investment Agreement, we entered into a Registration Rights Agreement with Tangiers. Pursuant to the Registration Rights
Agreement, we have filed a registration statement of which this prospectus is a part, covering the possible resale by Tangiers
of the shares that we issue to Tangiers under the Investment Agreement. Through this prospectus, Tangiers may offer to the public
for resale shares of our Common Stock that we issue to Tangiers pursuant to the Investment Agreement. The effectiveness of this
registration statement is a condition precedent to our ability to sell shares of Common Stock to Tangiers under the Investment
Agreement.
For a period of 36 months from the first trading day following
the effectiveness of this registration statement, we may, from time to time, at our discretion, and subject to certain conditions
that we must satisfy, draw down funds under the Investment Agreement by selling shares of our Common Stock to Tangiers. Each draw
down request must be for at least $5,000 and may, in our discretion, be up to the lesser of $500,000 and a formula amount based
on the average price and trading volume of our Common Stock over a designated period preceding the draw down request. The purchase
price of these shares will be at a discount to the lowest trading price of the Common Stock during a designated pricing period
following the draw down request. The formulas for determining the actual draw down amounts, the number of shares we issue to Tangiers
and the purchase price per share paid by Tangiers are described in detail below.
We are under no obligation to request a draw down for any period.
The aggregate total of all draws cannot exceed $10,000,000 and no single draw can exceed $500,000. In addition, the Investment
Agreement does not permit us to make a draw down if the issuance of shares to Tangiers pursuant to the draw down would result in
Tangiers and certain of its affiliates owning more than 4.99% of our outstanding Common Stock on the date we exercise a draw down.
Pursuant to the Registration Rights Agreement, we are registering 2,000,000 shares of Common Stock for possible issuance and resale
under the private equity line.
As consideration for its commitment to purchase shares of our
Common Stock pursuant to the Investment Agreement, we have issued to Tangiers 25,000 shares of our Common Stock and a common stock
purchase warrant (the “Warrant”) to purchase up to 1,100,000 shares of our Common Stock. The Warrant is exercisable
at a price of $1.25 per share, subject to adjustment, and contains cashless exercise provisions.
THE DRAW DOWN PROCEDURE AND THE STOCK
PURCHASES
We may request a draw down by delivering a draw down notice
to Tangiers, stating the share amount of the draw down we wish to exercise. The next five trading days including and immediately
following the draw down notice are used to determine the actual amount of money Tangiers will provide. On the draw down settlement
date the dollar amount of the draw is determined and delivered by Tangiers to the Company.
Amount of Each Draw Down
The share amount of the draw down is the
amount we have requested, with a minimum request of at least $5,000 and the maximum investment amount by Tangiers being the lesser
of:
|
|
●
|
200% of the average daily trading volume of the Common Stock during the 10 trading days immediately prior to the Company’s
draw down notice.
|
At no time is Tangiers required to purchase more than the maximum
investment amount for a given pricing period. As a result, if we choose not to exercise the maximum investment amount in a given
draw down pricing period Tangiers is not obligated to and will not purchase more than the scheduled maximum investment amount calculated
above in a subsequent draw down pricing period.
Purchase Price of each Draw Down
The purchase price of the shares we issue to Tangiers pursuant
to a draw down is the lowest trading price of the Common Stock during the five trading day period including and immediately following
the date of the Company’s draw down notice multiplied by 80%.
Conditions
Before Tangiers is obligated to buy any shares of our Common
Stock pursuant to a draw down, the following conditions, none of which is in Tangiers’ control, must be met:
|
|
●
|
The registration statement, which includes this prospectus, shall have previously become effective and shall remain effective.
|
|
|
●
|
At all times during the period beginning on the date of the relevant draw down notice and ending on the date of the closing
of any resale, the Common Stock shall have been listed or quoted for trading on the principal market on which the Common Stock
is traded and shall not have been suspended from trading thereon.
|
|
|
●
|
We shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required
by the Investment Agreement and the Registration Rights Agreement to be performed, satisfied or complied with by us.
|
|
|
●
|
No injunction shall have been issued and remain in force, or action commenced by a governmental authority which has not been
stayed or abandoned, prohibiting the purchase or the issuance of the shares.
|
|
|
●
|
The issuance of the shares of Common Stock will not violate any stockholder approval requirements of the principal market on
which the Common Stock is traded.
|
|
|
●
|
Each of our representations and warranties in the Investment Agreement shall be true and correct in all material respects as
of the date when made and as of the draw down exercise date.
|
|
|
●
|
Trading in our Common Stock shall not have been suspended by the SEC or FINRA and trading in securities generally on the principal
market shall not have been suspended or limited.
|
|
|
●
|
No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated,
endorsed or, to the knowledge of us, threatened by any court or governmental authority which prohibits the consummation of or which
would materially modify or delay any of the transactions contemplated by the Investment Agreement.
|
|
|
●
|
The Company shall have executed and delivered to Tangiers the certificates representing, or have executed electronic book-entry
transfer of, the shares of Common Stock being purchased.
|
There is no guarantee that we will be able to meet the foregoing
conditions or any other conditions under the Investment Agreement or that we will be able to draw down any portion of the amounts
available under the Investment Agreement.
Termination of the Investment Agreement
The Investment Agreement terminates (i) 36 months after the
Registration Statement is declared effective, (ii) when Tangiers has purchased an aggregate of $10,000,000 of Common Stock, (iii)
at any time the Registration Statement is no longer in effect, or, (iv) subject to certain exceptions set forth therein, at any
time upon 15 days’ written notice from the Company to Tangiers.
SELLING STOCKHOLDERS
This prospectus relates to the possible resale by the selling
stockholder named below of shares of the Company’s Common Stock that we may issue pursuant to the Investment Agreement we
entered into with Tangiers. We are filing the registration statement of which this prospectus is a part pursuant to the provisions
of the Registration Rights Agreement we entered into with Tangiers. References in this prospectus to the “selling stockholder”
means Tangiers, and any donees, pledgees, transferees or other successors in interest selling shares received after the date of
this prospectus from a selling stockholder as a gift, pledge or other non-sale related transfer.
The selling stockholder, who is deemed to be a statutory underwriter,
will offer their Shares at prevailing market or privately negotiated prices including (without limitation) in one or more transactions
that may take place by ordinary broker’s transactions, privately-negotiated transactions or through sales to one or more
dealers for resale or at prevailing market if a market should develop. Tangiers may from time to time offer and sell pursuant to
this prospectus any or all of the shares of Common Stock that it acquires under the Investment Agreement.
The distribution of the selling stockholders’ Shares may
be effected in one or more transactions that may take place through customary brokerage channels, in privately-negotiated sales,
by a combination of these methods or by other means. The selling stockholders may from time to time offer their shares through
underwriters, brokers-dealers, agents or other intermediaries. Usual and customary or specifically negotiated brokerage fees or
commissions may be paid by the selling stockholders in connection with sales of the Shares.
The distribution of the Shares by the selling stockholder may
be effected in one or more transactions that may take place through customary brokerage channels, in privately negotiated sales;
by a combination of these methods; or by other means. We do not know how long the selling stockholders will hold the shares before
selling them, and other than the Investment Agreement we entered into with Tangiers, we currently have no agreements, arrangements
or understandings with the selling stockholders regarding the sale of any of the Shares. The Company will not receive any portion
or percentage of any of the proceeds from the sale of the Shares.
The following table sets forth ownership
of shares held by each person who is a selling stockholder.
|
|
|
Before Offering
|
|
|
|
|
|
After Offering (2)
|
|
|
Name
|
|
Number of
Shares
Owned
|
|
|
Percent
of
Class (1)
|
|
|
Shares
Offered
for Sale
|
|
|
Number of
Shares
Owned
|
|
|
Percent
of
Class (1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tangiers Global, LLC
|
|
|
25,000
|
|
|
|
*
|
|
|
|
2,000,000
|
|
|
|
25,000
|
|
|
|
*
|
|
|
(1)
|
Based on 33,925,715 shares of Common Stock outstanding as of the date of this prospectus.
|
|
(2)
|
The columns in the table above reflecting “After Offering”: “Number of Shares Owned” and “Percent of Class” are prepared on the basis that all shares being registered in this registration statement are resold to third parties. Shares of our Common Stock being offered pursuant to this prospectus by a selling stockholder are counted as outstanding for computing the percentage of the selling stockholder.
|
DILUTION
Under the Investment Agreement, the purchase price of the shares
to be sold to Tangiers will be at a price equal to the lowest trading price of the Common Stock during the five trading day period
including and immediately following the date of the Company’s draw down notice (“Market Price”) multiplied by
80%. The table below illustrates an issuance of Common Stock to Tangiers under the Investment Agreement for a hypothetical draw
down amount of $500,000 at an assumed Market Price of $1.00:
|
Draw Down Amount
|
|
|
Price to be paid by Tangiers
|
|
|
Number of Shares to be Issued
|
|
|
|
|
|
|
|
|
|
|
|
$
|
500,000
|
|
|
$
|
0.80
|
|
|
|
625,000
|
|
By comparison, if the Market Price of the
Common Stock was $0.50, the number of shares that would be required to be issued in order to have the same draw down amount of
$500,000 would be greater, as shown by the following table:
|
Draw Down Amount
|
|
|
Price to be paid by Tangiers
|
|
|
Number of Shares to be Issued
|
|
|
|
|
|
|
|
|
|
|
|
$
|
500,000
|
|
|
$
|
0.40
|
|
|
|
1,250,000
|
|
Accordingly, there would be dilution of an additional 625,000
shares issued due to the lower stock price of $0.50 per share. In effect, if we are interested in receiving a fixed funding amount,
a lower price per share of our Common Stock means a higher number of shares to be issued to Tangiers in order to receive that fixed
funding amount, which equates to greater dilution of existing stockholders. The effect of this dilution may, in turn, cause the
price of our Common Stock to decrease further, both because of the downward pressure on the stock price that would be caused by
a large number of our shares sold to the public by Tangiers, and because our existing stockholders may disagree with a decision
to sell shares to Tangiers at a time when our stock price is low, and may in response decide to sell additional numbers of shares
of their own, further decreasing our stock price.
The actual number of shares that will be issued to Tangiers
under the Investment Agreement will depend upon the Market Price of our Common Stock at the time of our puts to Tangiers and shortly
thereafter. The price per share Tangiers ultimately pays for each share is determined by dividing the aggregate purchase price
by the number of shares we issue to Tangiers.
Additionally, under the Registration Rights Agreement, we are
registering 2,000,000 shares of Common Stock for possible issuance and resale under the private equity line. Notwithstanding that
Tangiers has committed to purchase, from time to time over a 36-month period, shares of our Common Stock for cash consideration
of up to an aggregate of $10,000,000 under the Investment Agreement, the likelihood that we would access the full $10,000,000 is
low. This is due to several factors including the fact that the Investment Agreement’s share volume limitations will limit
our use of the Investment Agreement and the market price may decrease and thus fewer dollars will be received by us as shares are
issued.
Even if we were able to put all of the 2,000,000 of the Shares
registered under this registration statement to Tangiers under the Investment Agreement at our current market prices, we would
only realize approximately $1,120,000 under the Investment Agreement based on current trading prices of our stock. We determined
to register in this registration statement a total of 2,000,000 shares, which represents less than one-third of our public float
(after subtracting the holdings of insiders and controlling stockholders) in order to allow the greatest possible flexibility under
the Investment Agreement. The number of shares that might be utilized under the Investment Agreement cannot be determined at this
time as it will fluctuate with the market price of our stock and our financial requirements. Should the Market Price require us
to issue more than 2,000,000 shares of Common Stock to Tangiers, we may need to subsequently register additional shares of our
Common Stock.
MARKET FOR OUR COMMON STOCK
Market Information
Prior to September 25, 2014 our Common Stock was quoted in the
OTC Markets under the trading symbol “FHGR”. On September 25, 2014 our trading symbol changed to “STWC”.
Our stock is currently quoted on OTCQB.
Holders
At August 8, 2019, we had approximately 168 holders of our Common
Stock. We have appointed Colonial Stock Transfer Co, Inc., 66 Exchange Place, Suite 100, Salt Lake City, UT 84111, to act as the
transfer agent of our Common Stock.
Dividends
We have never declared or paid any cash dividends on our Common
Stock since inception. We do not anticipate paying any cash dividends to stockholders in the foreseeable future. In addition, any
future determination to pay cash dividends will be at the discretion of the Board of Directors and will be dependent upon our financial
condition, results of operations, capital requirements, and such other factors as the Board of Directors deem relevant
Securities Authorized for Issuance under Equity Compensation
Plans
At January 31, 2019, our most recent year-end, we did not have
any compensation plan (including individual compensation arrangements) under which our Common Stock was authorized for issuance.
DESCRIPTION OF COMMON STOCK
The shares registered pursuant to the registration statement,
of which this prospectus is a part, are shares of Common Stock, all of the same class and entitled to the same rights and privileges
as all other shares of Common Stock.
The Articles of Incorporation originally authorized us to issue
up to 100,000,000 shares of $.00001 par value Common Stock. On August 20, 2019, the Board of Directors and a shareholder owning
in excess of two-thirds of the Company’s issued and outstanding common shares consented to an amendment to the Articles of
Incorporation to increase the total authorized number of shares to 500,000,000. On August 21, 2019, we filed a preliminary information
statement disclosing the increase in authorized shares which becomes effective 20 days following the filing and mailing of the
definitive information statement. On September 9, 2019, we filed a definitive information statement disclosing the increase in
authorized shares. On September 10, 2019, we filed articles of amendment with the State of Colorado to make the amendment increasing
the number of authorized shares effective on September 30, 2019. The holders of Common Stock, including the shares offered hereby,
are entitled to equal dividends and distributions, per share, with respect to the Common Stock when, as and if declared by the
Board of Directors from funds legally available therefore. No holder of any shares of Common Stock has a pre-emptive right to subscribe
for any securities of our company nor are any common shares subject to redemption or convertible into other securities of our company.
Upon liquidation, dissolution or winding up of our company, and after payment of creditors and preferred stockholders, if any,
the assets will be divided pro-rata on a share-for-share basis among the holders of the shares of Common Stock.
Each share of Common Stock is entitled to one vote with respect
to the election of any director or any other matter upon which shareholders are required or permitted to vote. Under our Articles
of Incorporation, holders of our company’s Common Stock do not have cumulative voting rights, so that the holders of more
than 50% of the combined shares voting for the election of directors may elect all of the directors, if they choose to do so and,
in that event, the holders of the remaining shares will not be able to elect any members to our board of directors.
PLAN OF DISTRIBUTION
General
The selling stockholder may seek an underwriter, broker-dealer
or selling agent to sell the Shares. As of the date of this prospectus, the selling stockholder has not entered into any arrangements
with any underwriter, broker-dealer or selling agent for the sale of the Shares. Other than the Investment Agreement we entered
into with Tangiers, the Company has no arrangements, nor has it entered into any agreement with any underwriters, broker-dealer
or selling agents for the sale of the Shares.
The selling stockholder and any underwriters, broker-dealers
or agents who participate in the sale or distribution of the Shares may be deemed to be “underwriters” within the meaning
of the Securities Act. As a result, any profits on the sale of the Shares by the selling stockholder and any discounts, commissions
or agent’s commissions or concessions received by any such broker-dealer or agents may be deemed to be underwriting discounts
and commissions under the Securities Act. If the selling stockholder is deemed to be an “underwriter” within the meaning
of Section 2(11) of the Securities Act, it will be subject to prospectus delivery requirements of the Securities Act. Underwriters
are subject to certain statutory liabilities, including, but not limited to, Sections 11, 12 and 17 of the Securities Act.
There can be no assurance that the selling stockholder will
sell any or all of the Shares under this prospectus. Further, we cannot assure you that the selling stockholder will not transfer,
devise or gift the Shares by other means not described in this prospectus. In addition, any Shares covered by this prospectus that
qualify for sale under Rule 144 or Rule 144A of the Securities Act may be sold under Rule 144 or Rule 144A in certain instances,
rather than under this prospectus.
The Shares covered by this prospectus may also be sold to non-U.S.
persons outside the U.S. in accordance with Regulation S under the Securities Act rather than under this prospectus. The Shares
may be sold in some states only through registered or licensed brokers or dealers. In addition, in some states the Shares may not
be sold unless they have been registered or qualified for sale or an exemption from registration or qualification is available
and complied with. If any of the Shares offered for resale pursuant to this prospectus are transferred other than pursuant to a
sale under this prospectus, the subsequent holders could not use this prospectus until a post-effective amendment to the registration
statement of which this prospectus is a part or a prospectus supplement is filed naming such holders.
The selling stockholder and any other person participating in
the sale of the Shares may be subject to the Exchange Act. The Exchange Act rules include, without limitation, Regulation M, which
may limit the timing of purchases and sales of any of the Shares by the selling stockholder and any other such person. In addition,
Regulation M may restrict the ability of any person engaged in the distribution of the Common Stock to engage in market-making
activities with respect to the particular Shares being distributed. This may affect the marketability of the Shares and the ability
of any person or entity to engage in market-making activities with respect to the Shares.
The Company intends to maintain the currency and accuracy of
this prospectus for a period of up to two years, unless earlier completely sold, pursuant to Rule 415 of the General Rules and
Regulations of the Securities and Exchange Commission.
Resales of the Shares under State Securities Laws
The National Securities Market Improvement Act of 1996 (“NSMIA”)
limits the authority of states to impose restrictions upon resales of securities made pursuant to Sections 4(a)(1) and 4(a)(3)
of the Securities Act of companies which file reports under Sections 13 or 15(d) of the Exchange Act. Resales of the Shares in
the secondary market will be made pursuant to Section 4(a)(1) of the Securities Act (sales other than by an issuer, underwriter
or broker).
LEGAL MATTERS
The validity of the shares of Common Stock offered under this
prospectus is being passed upon for us by Pearson Butler, PLLC, Attorneys at Law, South Jordan, Utah.
EXPERTS
Our financial statements for the years ended January 31, 2019
and 2018, appearing in this prospectus which is part of a registration statement have been audited by B
F Borgers CPA PC, and are included in reliance upon such reports given upon the authority of B
F Borgers CPA PC, as experts in accounting and auditing.
ADDITIONAL INFORMATION
We have filed a registration statement on Form S-1 under the
Securities Act of 1933, as amended, (SEC File No. 333-233429) relating to the shares of Common Stock being offered by this prospectus,
and reference is made to such registration statement. This prospectus constitutes the prospectus of STWC Holdings, Inc., filed
as part of the registration statements, and it does not contain all information in the registration statements, as certain portions
have been omitted in accordance with the rules and regulations of the Securities and Exchange Commission.
We are required to file reports and other documents with the
SEC. We do not presently intend to voluntarily furnish you with a copy of our annual report. You may read and copy any document
we file with the Securities and Exchange Commission at the public reference room of the Commission between the hours of 9:00 a.m.
and 5:00 p.m., except federal holidays and official closings, at 100 F Street, NE, Room 1580, Washington, D.C. 20549. You should
call (202) 551-8090 for more information on the public reference room. Our SEC filings are also available to you on the Internet
website for the Securities and Exchange Commission at http://www.sec.gov.
INCORPORATION OF CERTAIN INFORMATION
BY REFERENCE
The SEC permits us to “incorporate
by reference” the information contained in documents we file with the SEC, which means that we can disclose important information
to you by referring you to those documents rather than by including them in this prospectus. Information that is incorporated by
reference is considered to be part of this prospectus and you should read it with the same care that you read this prospectus.
Information that we file later with the SEC will automatically update and supersede the information that is either contained, or
incorporated by reference, in this prospectus, and will be considered to be a part of this prospectus from the date those documents
are filed.
We incorporate by reference the documents
listed below, all filings filed by us pursuant to the Exchange Act after the date of the registration statement of which this prospectus
supplement forms a part, and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the
Exchange Act prior to the time that all securities covered by this prospectus supplement have been sold; provided, however, that
we are not incorporating any documents or information deemed to have been furnished and not filed in accordance with SEC rules:
|
|
●
|
our Annual Report on Form 10-K for the fiscal year ended January 31, 2019, filed with the SEC on April 30, 2019 and its accompanying
amendment filed on May 2, 2019;
|
|
|
●
|
our Quarterly Report on Form 10-Q for the quarter ended April 30, 2019, filed with the SEC on June 14, 2019 and its accompanying
amendment filed June 19, 2019;
|
|
|
●
|
our Quarterly Report on Form 10-Q for the quarter ended on July 31, filed with the SEC on September 16, 2019;
|
|
|
●
|
Our definitive information statement of Schedule 14C filed with the SEC on September 9, 2019.
|
In addition, all documents subsequently
filed by us pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act before the date our offering is terminated or
completed are deemed to be incorporated by reference into, and to be a part of, this prospectus.
Any statement contained in this prospectus
or in a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified or superseded
for purposes of this prospectus to the extent that a statement contained in this prospectus or any other subsequently filed document
that is deemed to be incorporated by reference into this prospectus modifies or supersedes the statement. Any statement so modified
or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus.
We will provide to each person, including
any beneficial holder, to whom a prospectus is delivered, at no cost, upon written or oral request, a copy of any or all of the
information that has been incorporated by reference in the prospectus but not delivered with the prospectus. You should direct
any requests for copies to us at Attention: Erin Phillips, CEO, 1350 Independence Street, Lakewood, CO 80215 or you may call us
at (303) 736-2442. Exhibits to the filings will not be sent, however, unless those exhibits have specifically been incorporated
by reference into this prospectus.
You should rely only on information
contained in, or incorporated by reference into, this prospectus. We have not authorized anyone to provide you with information
different from that contained in this prospectus, or incorporated by reference in this prospectus and in any free writing prospectus
that we have authorized for use in connection with this offering. We are not making offers to sell the securities in any jurisdiction
in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified
to do so or to anyone to whom it is unlawful to make such offer or solicitation.
[OUTSIDE BACK COVER]
STWC
Holdings, Inc.
[A Colorado Corporation]
2,000,000 Shares
Common Stock
PROSPECTUS
STWC
Holdings, Inc.
1350 Independence Street
Suite 300
Lakewood, CO 80215
Telephone (303) 736-2442
September 10, 2019
Until December 9, 2019, all dealers that effect transactions
in our shares, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the
dealer’s obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.
STWC (CE) (USOTC:STWC)
Historical Stock Chart
From Feb 2025 to Mar 2025
STWC (CE) (USOTC:STWC)
Historical Stock Chart
From Mar 2024 to Mar 2025
